coteau ARQ.

VOGX

Vogenx, Inc.
$17.45
−$1.63 (8.54%) Oct 23 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-2%+39%+80%+121%+163%Aug 12Oct 23Sep 1752w low $12.95
VOGXSPY
Wall St. Highest PT $55.00 (+215.2%) Wall St. Avg PT $55.00 (+215.2%)
$13$29$44$60$75POC $17Hi $55Avg $55
Underwater Drawdown %Max DD -57.4%Current -48.9%
0.0%-57.4%
Relative Strength vs SPY+35.6% vs SPYOutperforming
+188%0%-188%
1W
+$2.92 (20.10%)
1M
−$9.41 (35.03%)
3M
–
6M
–
YTD
–
1Y
–

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Strong Buy
1 analyst · mean score 1.00
1 = Strong Buy · 5 = Sell
Wall Street consensus
Analyst price targets
Current price$17.45
Average target$55.00
+$37.55 (+215.2%) upsideaverage target vs current price
12-month Wall Street target range
Recent analyst rating changes · 2
Initiated
2026-09-02 · WBB Securities started covering VOGX at Speculative Buy
Initiated
2026-09-01 · Jones Trading started covering VOGX at Buy
All analyst rating changes ›

Third-party ratings, not Coteau's views.

Key stats & company

Market value$259.2M
52-week range$12.95 – $38.41
Dividend yieldNo dividend
Analyst consensusStrong Buy (1)
Average analyst price target$55.00 (+215%)

What they do

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D).

Healthcare · Biotechnology
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for VOGX yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 Coteau Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 Coteau Physical AI Grid & Power
Outside this model's universe or screens
 Coteau Long Book
Not in the current book

Earnings & events

VOGX earningsNo upcoming date on file
Source: Yahoo Finance · refreshed 2026-10-24 02:55:03 ET
No EPS history available.

Quarterly revenue

QuarterRevenueYoY
2026-06-30$0–
2026-03-31$0–
2025-06-30$0–
2025-03-31$0–

News & catalysts

More news
Top Premarket Gainers
MT Newswires · Oct 22
Vogenx Begins Phase 2b Trial of Mizagliflozin for Post-Bariatric Hypoglycemia
MT Newswires · Oct 15
Vogenx Initiates Phase 2b EMERGE Study of Mizagliflozin for Post-Bariatric Hypoglycemia
ACCESS Newswire · Oct 15
Vogenx Appoints Richard Gorman Chief Commercial Officer
MT Newswires · Oct 09
Vogenx Appoints Board Member Richard Gorman as Chief Commercial Officer
ACCESS Newswire · Oct 09
Rating changes
Initiated
2026-09-02 · WBB Securities started covering VOGX at Speculative Buy
Initiated
2026-09-01 · Jones Trading started covering VOGX at Buy

Third-party analyst actions, not Coteau's views. All rating changes

Stats refreshed 2026-10-24 02:55:03 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, Coteau model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

coteau

Free to use. No card, no ads, no auto-renew.

Independent research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026